Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
about
Harnessing the power of Vδ2 cells in cancer immunotherapyγδ T cells in cancer immunotherapyExpanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions.Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.Plasticity of γδ T Cells: Impact on the Anti-Tumor ResponseA quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronateMechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.Association of MICA-TM and MICB C1_2_A microsatellite polymorphisms with tumor progression in patients with colorectal cancer.Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulationCurrent progress in γδ T-cell biology.Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.Gamma Delta T-lymphocytes in Hepatitis C and Chronic Liver Disease.Potential Use of γδ T Cell-Based Vaccines in Cancer Immunotherapy.Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.Indications for Opioid Antagonists.Tuning cancer fate: the unremitting role of host immunity.Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+) γδ T cell cytotoxicity in a perforin-dependent manner.Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy.Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.Treatment With Naloxegol Versus Placebo: Pain Assessment in Patients With Noncancer Pain and Opioid-Induced Constipation.γδ T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors.A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
P2860
Q27027547-215CCDAD-C7D4-4733-A168-C163956B5EC2Q28068988-66B351FB-F2D2-443B-A052-E261E5E6DA23Q33938500-38EA9B7F-0448-416F-8E9F-C7156048F052Q34395222-DA30B2E8-DC3B-42A1-B3F2-3000D5A82874Q34652408-496DAA91-920B-4F97-A496-43A923314262Q34743969-3E8C127C-AEF0-4CBD-8774-36C7B93379E0Q35208161-DB928610-6E73-461F-86E6-56BD21551965Q36471673-9CAA8CE6-136E-4F05-B286-4D00A2D4ACB3Q36734208-E5FBC587-A78A-404F-9C0D-04F3567A6FBBQ36883879-C0CAE8C7-F299-4596-A869-ACEA2DC1B3B3Q37241707-D1ABB508-BBBA-42F8-AEB0-226E959DD5A3Q37655345-AA9FF437-3C3C-4BB7-94E5-09AD630ED47CQ37729208-A9CDCA3C-DA62-4054-BCFA-23E099260819Q37731978-80DA4A48-25C5-4161-9AD4-C5CC977B11EAQ38247990-E9A84B8B-4AEE-49FD-932C-8BBF9BD72FF1Q38265506-3AAEFB32-ACF6-48F2-A783-4B2EB2B150C2Q38310258-68BCA930-B8B1-4958-9A7B-A2AB741E8AE4Q38762441-4265028B-3A8D-4087-BB6D-2754F269540DQ39239026-8EE533E2-00D4-4391-B9BF-961C4F1987D0Q40213985-A8101072-2E23-4069-96F5-32AE2CFD6CAFQ40252845-B82D5E22-86BF-420C-B5DF-9274BC83912BQ42155981-2B62E3AF-9B42-4A9E-A0DA-5E24E6F668B5Q42573316-BB3F8AAC-3E17-47CC-8128-73507246B97EQ43075638-8BBD3DE1-5729-44F4-AC0B-748CDF95D034Q44348840-23FB1871-92CA-4160-85FE-525F17BF58CFQ52649705-0E058B14-2580-4F95-AB2D-B0BE72F7379AQ52731753-A2EA10B2-72E4-41A4-9DBD-EA613963CF8F
P2860
Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@ast
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@en
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@nl
type
label
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@ast
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@en
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@nl
prefLabel
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@ast
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@en
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@nl
P2093
P2860
P356
P1476
Vgamma9Vdelta2 T cell-mediated ...... lar and colorectal carcinomas.
@en
P2093
Cécile Thomas de la Pintière
Eric Dupont-Bierre
Florian Cabillic
Francoise Bouet-Toussaint
Karim Boudjema
Matthieu Le Gallo
Noëlle Genetet
Olivier Toutirais
Pascale Daniel
Véronique Catros
P2860
P304
P356
10.2217/14750708.5.4.531
P577
2007-09-01T00:00:00Z